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Abstract 
Background: Mapping of left ventricular (LV) native T1 is a promising non-invasive, non-contrast imaging biomarker. 
Native myocardial T1 times are prolonged in patients requiring dialysis, but there are concerns that the dialysis pro-
cess and fluctuating fluid status may confound results in this population. We aimed to assess the changes in cardiac 
parameters on 3T cardiovascular magnetic resonance (CMR) before and after haemodialysis, with a specific focus on 
native T1 mapping.
Methods: This is a single centre, prospective observational study in which maintenance haemodialysis patients 
underwent CMR before and after dialysis (both scans within 24 h). Weight measurement, bio-impedance body com-
position monitoring, haemodialysis details and fluid intake were recorded. CMR protocol included cine imaging and 
mapping native T1 and T2.
Results: Twenty-six participants (16 male, 65 ± 9 years) were included in the analysis. The median net ultrafiltration 
volume on dialysis was 2.3 L (IQR 1.8, 2.5), resulting in a median weight reduction at post-dialysis scan of 1.35 kg (IQR 
1.0, 1.9), with a median reduction in over-hydration (as measured by bioimpedance) of 0.75 L (IQR 0.5, 1.4). Significant 
reductions were observed in LV end-diastolic volume (− 25 ml, p = 0.002), LV stroke volume (− 13 ml, p = 0.007), 
global T1 (21 ms, p = 0.02), global T2 (− 1.2 ms, p = 0.02) following dialysis. There was no change in LV mass (p = 0.35), 
LV ejection fraction (p = 0.13) or global longitudinal strain (p = 0.22). On linear regression there was no association 
between baseline over-hydration (as defined by bioimpedance) and global native T1 or global T2, nor was there an 
association between the change in over-hydration and the change in these parameters.
Conclusions: Acute changes in cardiac volumes and myocardial native T1 are detectable on 3T CMR following hae-
modialysis with fluid removal. The reduction in global T1 suggests that the abnormal native T1 observed in patients 
on haemodialysis is not entirely due to myocardial fibrosis.
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Introduction
Patients with chronic kidney disease (CKD) are at a 
greatly increased risk of cardiovascular disease (CVD) 
[1]. This risk increases with severity of CKD [2], such that 
patients with CKD stage 5 are 3–4 times more likely to 
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experience a cardiovascular event than age-standardized 
patients without CKD [3]. In patients with kidney disease 
receiving dialysis, CVD remains the single most com-
mon cause of death, accounting for between 25 and 40% 
of all deaths [4–6]. CKD results in a unique cardiovas-
cular phenotype; with relatively fewer deaths due to ath-
erosclerotic processes and more due to sudden cardiac 
death and heart failure [4–8]. Cardiomyopathy of CKD, 
often called ‘uraemic cardiomyopathy’, refers to a spe-
cific pattern of myocardial fibrosis, left ventricular (LV) 
hypertrophy and diastolic dysfunction, which is found in 
patients with CKD and forms the pathological basis for 
this unique CVD phenotype [9–11].
Cardiovascular magnetic resonance imaging (CMR) is 
established as the reference method for imaging uraemic 
cardiomyopathy [12]. Previous studies using gadolinium-
enhanced CMR demonstrated the presence of myocardial 
fibrosis in patients on dialysis [13], and its association 
with poor survival [14]. However, the discovery of the 
association between gadolinium based contrast media in 
patients with CKD and the development of the very rare 
disease nephrogenic systemic fibrosis curtailed further 
research using this technique [15, 16]. There is a pressing 
need for an alternative marker of uraemic cardiomyopa-
thy, further intensified by the observation that regression 
of LV mass in isolation may not be robustly associated 
with improved CVD outcomes in patients with CKD 
[17]. Attempts to identify reliable imaging biomarkers in 
this population are hampered by the potential confound-
ing influence of the dialysis process itself and fluctuating 
fluid status.
Native T1 mapping is a non-contrast technique that 
estimates myocardial longitudinal relaxation times (ms) 
and reflects changes in extra- and intra-cellular compart-
ments. Myocardial T1 is commonly affected by changes 
in collagen (fibrosis), water (oedema), iron deposition 
(haemochromatosis, myocardial haemorrhage) and 
lipids (Anderson-Fabry’s disease) [18]. In addition, native 
T1 mapping has been shown to differentiate dialysis 
patients from both healthy [19] and co-morbid controls 
[20], with excellent inter-observer reproducibility [20, 
21]. Outside of the CKD population, T1 mapping has 
been shown to correlate well with myocardial fibrosis in 
other disease states [12, 22, 23]. However, the major con-
cern with using native T1 mapping in dialysis patients is 
the potential confounding influence on the T1 signal of 
changing tissue oedema resulting from the large intra-
dialytic fluid fluctuations that are typical of patients on 
intermittent haemodialysis [24]. A previous study using 
1.5T CMR observed small, but detectable, differences in 
native T1 times immediately after haemodialysis [25]. In 
the present study we assess the myocardial changes on 
3T CMR in response to haemodialysis with fluid removal, 
with a particular interest in native T1 to inform its poten-
tial suitability as a surrogate outcome measure in future 
therapeutic trials. We also explored the potential bias of 




Participants were aged > 40  years and were established 
on regular, day-time hospital-based haemodialysis for at 
least 6  months. Participants were eligible for inclusion 
if they had a history of recurrent fluid overload (defined 
as requirement for ultrafiltration volumes of at least 1.5 
L mean fluid removal over the preceding 3 dialysis ses-
sions) and without heart failure (defined as no previous 
clinical diagnosis of heart failure or with preserved LV 
ejection fraction (LVEF) (> 50%) on their most recent 
transthoracic echocardiogram). Participants had to be 
able to comply with study procedures, self-report an abil-
ity to lie flat for 1 h and provide informed consent. Exclu-
sion criteria included standard contra-indications to 
CMR and contraindications to iodine based radiological 
contrast (to facilitate a sub-study comparing CMR with a 
novel contrast CT technique) [26, 27]. The study was pro-
spectively registered at clinicaltrials.gov (NCT03704701). 
Favourable ethical opinion was granted by the West 
of Scotland Research Ethics Committee 1 (Ref: 18/
WS/0138, 13th August 2018). All study procedures were 
carried out in accordance with local guidelines and regu-
lations and with respect to the Declaration of Helsinki.
Study protocol
This single centre observational study consisted of 2 vis-
its (Fig. 1). Visit 1 occurred before a participant’s routine 
dialysis session. Where possible, this occurred at the end 
of a participant’s ‘long’, or two-day, gap, i.e., on a Monday 
for participants on a Monday, Wednesday, Friday dialy-
sis schedule. Participants on a morning dialysis schedule 
attended visit 1 the afternoon before dialysis. Between 
visits 1 and 2 participants were asked to consume food 
and drink as they normally would but to document what 
they had taken. Participants would then attend their rou-
tine haemodialysis session which was performed as per 
usual clinical practice. Details of the dialysis session were 
recorded including duration, ultrafiltration volume, set-
tings and medications administered. Visit 2 occurred 
after dialysis. Participants on an afternoon dialysis sched-
ule attended visit 2 the following morning. At each visit, 
weight measurement, bioimpedance body composi-
tion monitoring (using a Fresenius Body Composition 
Monitor, Fresenius Medical Care, Hong Kong as per 
manufacturer’s instructions), blood tests and CMR were 
performed.
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CMR image acquisition
CMR acquisition was performed at the Clinical 
Research Imaging Facility of the Queen Elizabeth Uni-
versity Hospital in Glasgow using a 3  T CMR scanner 
(PRISMA, Siemens Healthineers, Erlangen, Germany) 
with an 18-channel surface coil placed anteriorly and a 
32-channel spine coil placed posteriorly. Following the 
acquisition of localiser images, balanced steady state 
free precession sequences were used to acquire LV cine 
imaging in three long axis planes, followed by a short 
axis stack from the apex to the atrio-ventricular ring, 
each with 25 phases. Images were obtained using retro-
spective electrocardiogram (ECG)-gating at end-expi-
ration. Where participants were unable to breath-hold 
or had cardiac arrhythmia, compressed sensing (CS 
cardiac Cine, Siemens Healthineers) was used to allow 
real-time acquisition. Typical scan parameters were: 
field of view (FOV) 340 × 286 mm, slice thickness 7 mm 
with 3  mm gap in short axis stack, repetition time 
(TR)—41.4 ms, echo time (TE) 1.51 ms, flip angle 50°, 
voxel size 1.33 × 1.33 × 7 mm.
For native T1 and T2 mapping, basal, mid and api-
cal short axis views were acquired using SiemensMy-
oMaps sequences. For native T1, non-contrast, 
motion-corrected, optimized, modified Look-Locker 
inversion recovery sequences were used with the fol-
lowing typical parameters: FOV 340 × 272  mm, slice 
thickness 6.0  mm, voxel size: 1.9 × 1.9 × 6.0  mm, TR 
272  ms, TE 1.12  ms, flip angle 35 degrees, minimum 
T1 100 ms, inversion-time increment 80 ms, bandwidth 
1085 Hertz/pixel. For T2 mapping, three T2 weighted 
measurements were acquired followed by an automated 
exponential fit for each pixel after respiratory motion 
correction. The imaging used a T2-prepared single shot 
Fig. 1 Flow chart depicting study procedures
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balanced steady state free precession readout with T2 
preparation times (TE) = 0, 25, and 55 ms with a recov-
ery period of 3 heartbeats between measurements. 
Typical protocol parameters for T2 mapping were: FOV 
360 × 270 mm, slice thickness 8 mm, matrix 192 × 108, 
spatial resolution 1.9 × 2.5  mm, TR 207.39  ms, TE 
1.32  ms, flip angle 12 degrees, bandwidth 1184  Hz/
pixel.
CMR image analysis
All CMR scans were subject to a clinical report for clini-
cal governance purposes. Research CMR analysis was 
performed utilizing dedicated CMR software (cvi42, 
version 5.10, Circle Cardiovascular Imaging, Calgary, 
Alberta, Canada)). Routinely reported CMR measures of 
LV and right ventricular (RV) function were carried out 
according to current guidelines [28]. Parameters of myo-
cardial mass and volumes were not indexed to body sur-
face area to avoid confounding impact of weight changes 
falsely adjusting body surface area and is acceptable given 
the analysis of within-subject comparisons. Ventricu-
lar endocardial and epicardial contours were manually 
drawn at end-diastole (Fig.  2). LV endocardial contours 
were drawn at end-systole, which was deemed to be the 
phase with the smallest blood pool cavity. Papillary mus-
cles were excluded from myocardial mass and included 
in volumes. LV thickness was recorded as the maximum 
septal thickness measured perpendicular to the cavity 
on a short-axis mid-chamber view, at the approximate 
level of the mitral valve leaflet tips. Global LV strain (cir-
cumferential, longitudinal, and radial) and global RV 
strain (longitudinal and radial) were derived using the 
software’s tissue tracking module to determine peak val-
ues for each parameter. Atrial volumes were manually 
drawn on 4-chamber horizontal long axis views at atrial 
systole and diastole (defined with respect to mitral valve 
closure) to report maximum and minimum right atrial 
(RA) volumes and atrial emptying fraction. For left atrial 
(LA) measurements, the vertical long axis views were 
additionally contoured to report biplanar derived val-
ues. For T1 and T2 measurements, scanner derived maps 
were used. Epi- and endocardial borders were manually 
drawn on each basal, mid and apical map. Areas of obvi-
ous artefact were excluded from regions of interest (ROI) 
and care was taken to include only myocardial tissue 
with a 10% epi- and endocardial offset applied. Global 
values were derived by averaging results from all three 
short axis slices. Septal values were reported as the mean 
of segments 2, 3, 8, 9 and 14 as per the American Heart 
Association’s 16 segment model [29]. For blood pool T1 
and T2, ROIs were drawn within the LV cavity on the 
mid-LV map, with care taken to avoid artefact and papil-
lary muscles. Additional ROIs were manually drawn on a 
representative area of skeletal muscle, with the pectora-
lis major muscle used preferentially. A further ROI was 
drawn within a homogenous region within the right lobe 
of liver. The primary observer (AJR) batch analysed all 
CMRs in a random order and was blinded to participant 
identity and whether the scan was pre-or post-dialysis. A 
second independent observer (KM) analysed a random 
sample of > 20% of the cohort to assess inter-observer 
variability. As a post-hoc experiment, a T1MES phan-
tom [30] was scanned on consecutive days at times that 
replicated the study schedule to assess inter-study T1 
variability.
Statistical analysis
Continuous data with a normal distribution are pre-
sented as mean ± standard deviation (SD), and median 
and interquartile range (IQR) for skewed data, with nor-
mality defined according to Shapiro–Wilk test. Pre and 
post dialysis CMR values were compared using paired 
t-tests and Wilcoxon singed rank tests accordingly. Lin-
ear regression and multiple regression were used to com-
pare change in CMR parameters according to baseline 
variables. Repeated measures MANCOVA was used to 
account for covariates in the comparison of myocardial 
native T1 before and after dialysis. Intra- and interob-
server variability was assessed by the intra-class corre-
lation (ICC) coefficient (two-way mixed effect, average 
measures). Statistical analysis was performed, and fig-
ures created, using SPSS (version 27, Statistical Package 
for the Social Sciences, International Business Machines, 
Inc., Armonk, New York, USA).
Sample size
A prospective sample size calculation determined that a 
total of 9 participants would be required to detect a 2.5% 
difference in native T1 times with 80% power and alpha 
0.05 based on previously published data [19, 21]. A total 
of 22 participants would be sufficient to detect a 1.5% dif-
ference. A target of 30 participants was set to allow drop 




Twenty-eight participants were recruited between 19th 
October 2018 and 9th March 2020. Recruitment was 
stopped early (target n = 30) due to the COVID-19 pan-
demic. Two participants withdrew consent prior to 
any study procedures leaving 26 for analysis, of whom 
16 (61.5%) were male, 22 (84.6%) were white and age 
64.7 ± 9.4 years. Median duration of kidney replacement 
therapy at time of recruitment was 2.0 (1.3, 4.0) years. 
Multi-morbidity was prevalent in the cohort with a mean 
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Fig. 2 Representative 3T CMR images of mid- left ventricle end-diastolic short axis stack cine (A, B), end-diastolic horizontal long axis cine (C, D), 
native T1 mapping (E, F) and native T2 mapping (G, H) acquired before and after dialysis. In this representative participant, global T1 and global T2 
reduced following 4 h of haemodialysis with 2.3 L ultrafiltration
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Charlson Comorbidity index of 6 (mean modified Charl-
son Comorbidity Index of 3) [31, 32]. The median dura-
tion of haemodialysis treatment session was 4.0  h (4.0, 
5.0) with a mean blood flow of 265 (± 32) ml/min. Eight-
een (69.2%) participants followed an afternoon dialysis 
schedule and underwent dialysis median 2.5 (2.0, 2.8) 
hours after their first CMR, with repeat CMR at median 
15.3 (14.8, 16.7) hours after completion of dialysis. The 
remaining 8 (30.8%) participants followed a morning 
dialysis schedule and underwent dialysis at median 16 
(14.7, 16.2) hours after their first CMR, with a repeat 
CMR 1.5 (1.2, 2.7) hours after completing dialysis. For 
23 (88.5%) participants, visit 1 took place after their ‘long 
gap’ between dialysis sessions (i.e., pre-dialysis on a Mon-
day for a patient on a Monday, Wednesday, Friday dialysis 
schedule). Additional baseline characteristics are detailed 
in Additional file 1: Table S1. In 6 participants, clinically 
significant incidental findings were detected, including 2 
cancers requiring treatment (Additional file 1: Table S2).
Fluid status
All participants had a history of recurrent fluid overload 
with mean ultrafiltration volume of 2.2 L (± 0.4) from 
the preceding 3 dialysis sessions prior to recruitment. At 
visit 1 (pre-dialysis), 12 participants had demonstrable 
pitting oedema. 1 participant was unable to undergo bio-
impedance monitoring for multifactorial reasons (body 
habitus, immobility, skin emollient). Of the remaining 
25 participants, the median over-hydration was + 0.4 
L (−  2.8, + 3.5), with 10 participants measuring as vol-
ume deplete pre-dialysis. The median net ultrafiltration 
volume on dialysis was 2.3 L (1.8, 2.5) at a mean rate of 
6  mL/kg/h (± 1.7). Five participants experienced symp-
tomatic intradialytic hypotension requiring adjustment 
of their dialysis prescription. Between visit 1 (pre-dial-
ysis) and visit 2 (post-dialysis), the median estimated 
fluid intake was 0.9 L (0.6, 1.0). At visit 2 (post-dialysis), 
the median reduction in body weight was 1.4  kg (1.0, 
1.9), with a median reduction in over-hydration of 0.8 L 
(0.5, 1.4). No participants gained weight between visit 1 
and visit 2, albeit 2 participants’ weight did not change. 
According to bioimpedance monitoring, 3 participants 
increased their over-hydration between visits (range 0.2–
0.4 L).
CMR parameters pre‑ and post‑dialysis
Table 1 shows the CMR results before and after dialysis. 
Notable findings include a significant reduction in LV 
end-diastolic volume, LV stroke volume, RV stroke vol-
ume, LA volumes, global circumferential strain, global 
native T1, septal native T1 and global T2 following dialy-
sis. There was no change in LV mass, LV or RV ejection 
fraction or global longitudinal strain (Table  1). Figure  3 
shows within-subject changes for LV mass, LVEF, LA 
maximum volume, global T1, septal T1 and global T2. 
The intra- and interobserver reproducibility for global 
T1 was excellent with ICC of 0.989 and 0.949, respec-
tively. Additional intra- and interobserver reproducibility 
results are included in Additional file 1: Table S3.
Change in native T1 and T2 by fluid status
On linear regression there was no relationship between 
baseline over-hydration and global native T1, septal 
T1 or global T2 (Fig.  4). There was also no relationship 
between the change in global T1, septal T1 or global 
T2 with ultrafiltration volume (p = 0.88), change in 
over-hydration (p = 0.87) or change in weight (p = 0.95) 
(Fig.  4). There was no difference in the mean change in 
global native T1, septal T1 and global T2 in individuals 
who did versus did not achieve > 0.5 L reduction in over-
hydration (change in global T1: 11.3 (95% CI −  30.2, 
52.8), p = 0.58; septal T1: 0.24 (95% CI −  41.8, 42.3), 
p = 0.99; global T2: − 0.65 (95% CI − 2.1, 0.81), p = 0.37) 
nor in those with or without > 1.0  kg weight change 
(change in global T1: 6.3, (95% CI − 39.4, 52.0) p = 0.78; 
septal T1: 1.2 (95% CI − 45.6, 48.1), p = 0.95; global T2: 
0.09, (95%CI − 1.5, 1.7), p = 0.91). Blood pool native T1 
correlated with the degree of overhydration measured on 
bioimpedance at baseline  (r2 = 0.247, p = 0.013) but there 
was no association between the change in blood pool T1 
and the change in overhydration. There was also no cor-
relation between the change in in myocardial native T1 
time and the change in blood pool T1 (r = 0.13, p = 0.54), 
nor the change in haematocrit (r = − 0.25, p = 0.22). On 
repeated measures MANCOVA, when the change in 
blood pool T1 and the change in haematocrit were added 
as covariates to the comparison of myocardial native T1 
time, there was no significant interaction between either 
covariate and the change in myocardial native T1. Both 
covariates had small, non-significant contributions to 
the observed effect (change in blood pool T1 (partial eta 
squared 0.06, p = 0.72); change in haematocrit (partial eta 
squared 0.11, p = 0.11), resulting in an adjusted p-value of 
0.050 for the comparison of myocardial naïve T1 before 
and after dialysis. Additional determinants of blood T1 
are examined in Additional file 1: Table S4.
Change in native T1 and T2 parameters by dialysis session
There was no association between the change in 
global native T1, septal T1 or global T2 and the time 
from dialysis until repeat CMR (p = 0.80, 0.55 and 
0.77 respectively, when mean change in values was 
compared between morning and afternoon dialy-
sis patients). Eighteen participants were on a morn-
ing dialysis schedule, whereas 8 were on an afternoon 
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schedule and thus scanned at different times of day. 
The mean difference in myocardial native T1 pre/post 
dialysis was 25  ms in the morning group (n = 8) and 
20 ms in the afternoon group (n = 18), with no signifi-
cant difference between the groups (p = 0.80). When 
the T1MES phantom was scanned on consecutive days 
the measured T1 was 1216 ± 8  ms and 1215 ± 13  ms, 
respectively. The same values for T2 were 80.8 ± 0.9 ms 
and 80.2 ± 1.9 ms. There was no difference in global T1, 
septal T1 or global T2 in those participants who expe-
rienced symptomatic intradialytic hypotension versus 
those who did not (p = 0.87, 0.67 and 0.99, respec-
tively). All but 1 participant were prescribed regular 
intravenous iron therapy. Excluding the 5 participants 
who received intravenous iron between visit 1 and visit 
2 did not change the results (Additional file 1: Table S5).
Change in LV ejection fraction
There was no overall change in LVEF following dialysis 
(Table 1). Six participants had abnormal LVEF pre-dial-
ysis based on age and sex standardised reference ranges 
[33]. In 5 of these participants, LVEF improved following 
dialysis and fluid removal (range 3–9.5%). However, 11 
participants with normal LVEF pre-dialysis, had abnor-
mal LVEF post-dialysis. In one participant, a dramatic 
reduction in LVEF was clearly due to tachy-arrhythmia. 
In the remaining 10 participants, 4 had minor changes 
Table 1 Cardiovascular Magnetic resonance (CMR) parameters pre- and post-dialysis
Displayed as mean, standard deviation and paired t-test for variables with a normal distribution, and median, interquartile range and Wilcoxon signed rank test for 
those with a skewed distribution
The scanner-specific reference range for myocardial native global T1 in healthy subjects is mean (range) 1170 ms (1107–1234) and global T2 is mean 39.5 ms (34.7–44.3) 
(unpublished data, correspondence from Dr Kenneth Mangion and Dr Andrew Morrow)
LV left ventricular, RV right ventricular, LA left atrial, RA right atrial
CMR parameter Pre‑dialysis Post‑dialysis p‑value
LV myocardial mass (g) 103.8 (78.8, 142.4) 97.5 (78.2, 136.0) 0.35
LV end diastolic volume (ml) 185 (159, 229) 160 (152, 220) 0.002
LV end systolic volume (ml) 88 (71, 113) 84 (69, 111) 0.81
LV stroke volume (ml) 103 (± 29) 90 (± 30) 0.007
LV ejection fraction (%) 53.6 (48.6, 59.5) 49.8 (46.2, 54.5) 0.13
LV global longitudinal strain (%) − 13.8 (± 3.3) − 13.1 (± 3.6) 0.22
LV global circumferential strain (%) − 16.3 (− 19.5, − 14.0) − 15.1 (− 16.9, − 13.4) 0.03
LV global radial strain (%) 22.2 (± 6.7) 20.7 (± 7.1) 0.18
LV thickness (mm) 10.2 (8.4, 12.2) 10.6 (8.8, 12.3) 0.44
RV end diastolic volume (ml) 161 (133, 184) 136 (128, 171)  < 0.001
RV end systolic volume (ml) 67 (56, 82) 62 (53, 75) 0.66
RV stroke volume (ml) 98 (± 30) 84 (± 26)  < 0.001
RV ejection fraction (%) 56.9 (± 10.5) 53.8 (± 12.6) 0.05
RV global longitudinal strain (%) − 22.5 (± 5.9) − 22.4 (± 6.8) 0.88
RV global radial strain (%) 48.3 (37.2, 66.7) 49.8 (40.0, 71.7) 0.77
Minimum LA volume (ml) 44 (28, 70) 40 (22, 70) 0.001
Maximum LA volume (ml) 96 (75, 108) 86 (57, 101) < 0.001
Minimum RA volume (ml) 30 (20, 44) 29 (22, 41) 0.95
Maximum RA volume (ml) 60 (49, 77) 54 (45, 75) 0.09
Global native T1 (ms) 1283 (± 51) 1262 (± 49) 0.02
Septal native T1 (ms) 1313 (± 54) 1293 (± 47) 0.04
Blood pool native T1 (ms) 1957 (± 68) 1935 (± 73) 0.08
Skeletal muscle native T1 (ms) 1218 (± 65) 1210 (± 73) 0.60
Liver native T1 (ms) 686 (± 157) 679 (± 146) 0.45
Global T2 (ms) 42.2 (40.9, 44.8) 41.0 (39.9, 44.7) 0.02
Blood pool T2 (ms) 101.1 (± 20.9) 111.0 (± 24.5) 0.06
Skeletal muscle T2 (ms) 32.2 (± 2.1) 30.8 (± 3.0) 0.03
Liver T2 (ms) 21.6 (19.9, 23.5) 21.3 (20.1, 22.4) 0.81
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(< 5% difference) that crossed the threshold for age and 
sex standardised normal values, while 6 had > 5% reduc-
tion in LVEF but without obvious association between the 
change in LVEF and baseline hydration status (visit 1 bio-
impedance hydration status ranging from −  3.8 to + 2.5 
L). On multivariable linear regression including baseline 
Fig. 3 Within subject changes pre- and post- dialysis for left ventricular mass (A), left ventricular ejection fraction (B), left atrial maximum volume 
(C), global T1 times (D), septal T1 times (E), and global T2 times (F)
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over-hydration, baseline LVEF, ultrafiltration volume, 
follow-up over-hydration, over-hydration change, weight 
change, time from visit 1 until dialysis and time from 
dialysis until repeat CMR, only baseline LVEF and the 
time from visit 1 until dialysis significantly associated 
with the change in LVEF following a backwards elimina-
tion approach (baseline LVEF: Beta 0.43, p = 0.02; Time 
from CMR 1 until dialysis: Beta 0.38, p = 0.04; adjusted 
 r2 for the model = 0.30). At lower baseline LVEF, repeat 
LVEF was more likely to increase, whereas those who had 
a longer gap between visit 1 CMR and dialysis were more 
likely to have a reduction in LVEF at visit 2 (Fig. 5).
Discussion
This prospective study identified significant changes in 
cardiovascular parameters on 3T CMR in response to 
haemodialysis with fluid removal. Specifically, LV and 
RV end-diastolic volumes, stroke volumes, and atrial 
volumes reduced, as did global native T1, septal native 
T1 and global T2 times but not LV mass. There was no 
correlation between the change in these parameters and 
the change in fluid status measured by bodyweight or 
bioimpedance. The change in myocardial native T1 time 
was independent of changes in haematocrit and blood 
pool T1, suggesting that the observed difference is not 
explainable by reduced intravascular T1 time. Regardless 
of whether the change in native T1 time is due to fluid 
removal, or the dialysis process itself, the present results 
question the validity of native T1 mapping as a sur-
rogate marker for myocardial fibrosis in patients on 
haemodialysis.
Native T1 mapping is an appealing potential biomarker 
for myocardial fibrosis, with proven superiority over 
volumes, function and late gadolinium enhancement in 
patients with non-ischaemic dilated cardiomyopathy [34, 
35], and encouraging data in patients with CKD [18, 36, 
37]. However, there are conflicting results from previous 
studies exploring the influence of fluid status on native 
T1 mapping in patients with CKD. Native T1 times do 
not alter with varying end-diastolic volumes (an indica-
tor of changing fluid status) in patients on dialysis [21]. 
Similarly, a study comparing 124 dialysis patients to 137 
healthy controls found that the increased myocardial 
native T1 times observed in patients with CKD occurred 
independently of changes in T2 times, suggesting that 
fibrosis, rather than fluid, accounts for the differences in 
T1. However, these patients were scanned the day after 
dialysis when euvolaemia is most likely [38]. Furthermore, 
a study of 12 patients found no change in T1 values on 3T 
CMR immediately post dialysis [39]. These patients had 
relatively low ultrafiltration volumes (mean 1.1 L) and the 
lack of effect could be explained by insufficient time to 
Fig. 4 Scatter plots of global T1, septal T1 and global T2 according to baseline over-hydration (A–C respectively), and the change in global T1, 
septal T1 and global T2 according to change in weight (D–F respectively). There was no significant association in any of the comparisons
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allow for fluid re-equilibration. In the MIDNIGHT study 
[40], which found significant improvements in native T1 
time on 3T CMR with extended hours nocturnal haemo-
dialysis, there was no association between native T1 time 
and fluid status on bio-impedance body composition 
monitoring. However, the change in T1 did occur in the 
presence of increased ultrafiltration volumes in the treat-
ment group, and reduced ultrafiltration volumes in the 
control group. In contrast, a study of 30 dialysis patients 
found a significant correlation (r = 0.409) between fluid 
status and native T1 time on 1.5T CMR [24]. This result 
could be explained by reverse causality, with patients 
with more myocardial fibrosis being more prone to fluid 
overload. Kotecha et al. found global native T1 times on 
1.5T CMR reduced from 1085 ms pre-dialysis to 1072 ms 
post-dialysis in 25 dialysis patients undergoing a 3  h 
dialysis session with mean 2.0 L ultrafiltration [25]. The 
present study confirms this result at 3T and supports the 
conclusion that the abnormal native T1 times observed 
in patients with CKD can be modulated by dialysis with 
fluid removal and therefore is not entirely due to fibrosis.
The minimal clinically significant change in native T1 
time is difficult to define. Previous studies comparing 
native T1 in patients on dialysis versus controls found 
a mean difference of 21 ms on 1.5T [19] and 185 ms on 
3T [20]. In the present study, the mean global T1 are 
greater than the scanner-specific healthy reference range 
by a mean of 113 ms pre-dialysis and 91 ms post dialy-
sis (Table 1). The mean change in T1 time pre- and post-
dialysis was 21  ms. In the MIDNIGHT trial [40], the 
intervention resulted in a mean reduction in native T1 
time of 31 ms (from a mean baseline value of 1270 ms). 
As another example, in non-CKD patients undergoing 
aortic valve replacement, native T1 times reduced by 
an average of 45 ms and were associated with improved 
prognosis [41]. So while the difference in global T1 
observed by this study, and by Kotecha et  al. [25], is 
small, it is within the region of clinically significant differ-
ence. Similar magnitude of change has been observed in 
healthy volunteers and patients with coronary artery dis-
ease immediately post exercise, but in this setting native 
T1 times increased, rather than decreased [42]. In these 
patients with coronary artery disease, the magnitude of 
native T1 reactivity correlated with the severity of myo-
cardial perfusion abnormality [42]. This suggests that any 
change in native T1 times following dialysis is unlikely to 
be due to dialysis-induced ischaemia (which would cause 
times to increase).
Native T1 predicts outcome in patients with heart 
failure [34] and acute myocardial injury [43]. It also has 
proven diagnostic or prognostic benefit in a range of 
other conditions including amyloidosis, myocarditis, 
aortic stenosis, iron overload, and Anderson-Fabry dis-
ease [12, 44]. The present results question the on-going 
consideration of native T1 mapping as a surrogate for 
myocardial fibrosis in patients on haemodialysis. Stud-
ies including myocardial biopsy data will be needed 
to answer this definitively but would be challenging to 
justify ethically and difficult to complete. There is an 
ongoing study correlating native T1 mapping with post-
mortem histology in 9 participants (ClinicalTrials.gov 
Identifier: NCT03586518). For native T1 to proceed as a 
potential biomarker in CKD patients, it will require lon-
gitudinal studies with standardised timing of imaging in 
relation to dialysis therapy to establish if native T1 has a 
prognostic role in the CKD population, and if changes in 
native T1 times correspond with proportional changes in 
prognosis. If proven, the small changes in native T1 fol-
lowing dialysis may be deemed negligible.
Global T2 times reduced following dialysis with fluid 
removal, in keeping with previous studies [25]. The native 
transverse relaxation time (T2) is sensitive to proton 
Fig. 5 Scatter plots of change in left ventricular ejection fraction 
(LVEF) [calculated by visit 2 post-dialysis LVEF (%)—visit 1 pre-dialysis 
LVEF (%)] by baseline LVEF (p = 0.02) (A) and time from visit 1 CMR 
until dialysis (p = 0.04) (B)
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(water) binding to macromolecules and proton mobil-
ity. Native T2 reflects tissue water content and mobility 
to a greater extent than native longitudinal relaxation 
time (T1). Skeletal muscle T2 times also decreased sug-
gesting that the observed myocardial change may be 
due to reduced total body water content, rather than a 
myocardial-specific process, but there was no change in 
hepatic or blood pool T2. The timing of radiofrequency 
pulse sequence used in T2-weighted images results in 
increasing signal intensity with increasing water content 
of tissues [45], and so it is physically plausible that the 
change in T2 represents reduced tissue oedema. The lack 
of association between the change in T2 and the change 
in fluid status is against this, but it still remains the most 
likely explanation.
There appears to be a complex relationship with 
regards to parameters of ventricular function and dialysis 
with fluid removal. A study using intradialytic CMR has 
previously shown that LVEF drops acutely during dialy-
sis with incomplete recovery evident at 1 h post dialysis 
[39]. This explains the present observation whereby the 
timing of dialysis and repeat CMR was a significant fac-
tor in predicting repeat LVEF (albeit with a very weak 
correlation), with those patients on a morning dialysis 
schedule (and therefore undergoing repeat CMR soon 
after dialysis) being more likely to have a reduction in 
repeat LVEF. Paradoxically, in the sub-group of patients 
with reduced LVEF, previous reports have suggested that 
dialysis with fluid removal can improve LVEF [25]. In the 
present study, 5 of the 6 patients with abnormal LVEF at 
visit 1 had an improvement on repeat LVEF measure-
ment, presumably due to reduced afterload. With regards 
to clinical practice, CMR scanning should be avoided 
immediately post-dialysis and serial scanning should 
be performed at same time in relation to dialysis sched-
ule. Given the differential response in LVEF depend-
ing on baseline LVEF, it is conceivable that the wrong 
dialysis prescription could perpetuate a patient’s cardiac 
dysfunction and is a reminder of the importance of the 
individualised medicine in dialysis prescribing. There is 
increasing interest in the role of LV global longitudinal 
strain as a potentially superior measure of cardiac func-
tion compared to LVEF, especially in patients with CKD 
[36, 46]. Encouragingly, LV global longitudinal strain did 
not differ pre- and post-dialysis, suggesting it may give a 
consistent, volume-independent assessment of cardiac 
function in dialysis patients.
Limitations
This study addresses important questions in relation to 
3T CMR to inform timing of clinical scanning in rela-
tion to dialysis and the potential bias of fluid overload in 
parametric mapping. The cohort is representative of the 
wider dialysis population with high prevalence of comor-
bidity and no changes to their prescribed dialysis session. 
The number of clinically relevant incidental findings that 
were identified is striking but is in keeping with previ-
ous reports [47]. Fluid assessment was comprehensive 
and CMR scans were performed utilising state-of-the-
art hardware and software. However, there are several 
limitations. The sample was heterogeneous with regards 
to timing of scans in relation to dialysis, baseline LVEF 
(despite attempts to control this by excluding patients 
with known LV dysfunction) and baseline hydration sta-
tus, with 10 participants measuring as volume deplete on 
bioimpedance monitoring at visit 1. We cannot discount 
a Type 2 error for the lack of correlation between myo-
cardial native T1 and fluid removal. Further, there may 
have been a differential time-course between changes 
in fluid status and native T1. The impact of 1 L fluid 
removal is likely to have differential effect on the myocar-
dium if the starting state is volume overload, as opposed 
to volume depletion. Nevertheless, there was no appar-
ent difference in change in native T1 times according 
to baseline hydration status. The study could have been 
improved by inclusion of a control group who underwent 
dialysis without fluid removal. Further work is warranted.
Conclusion
Acute changes in cardiac volumes and myocardial com-
position are detectable on 3T CMR following haemo-
dialysis with fluid removal. Accordingly, the timing of 
clinical CMR scanning in relation to a patient’s dialy-
sis schedule is crucial, particularly if serial scanning is 
required. Small, but significant, reductions in global 
myocardial T1 and T2 relaxation times were observed 
after dialysis suggesting that the abnormal native T1 
signal in patients undergoing haemodialysis is not 
entirely due to fibrosis. The exact mechanism for the 
reduction in native T1 is unclear. Despite the lack of 
association with the change in native T1 and the change 
in fluid status, alterations in tissue oedema remain the 
most likely explanation, albeit removal of uraemic fac-
tors or the haemodynamic effects of dialysis itself may 
also contribute. Future studies examining the prognos-
tic capabilities of native T1 in CKD populations are still 
warranted but will require careful standardisation of 
imaging schedules and awareness of the potential con-
founding effect of fluid status and the dialysis process.
Abbreviations
CKD: Chronic kidney disease; CMR: Cardiovascular magnetic resonance; CVD: 
Cardiovascular disease; ECG: Electrocardiogram; LA: Left atrium/left atrial; LV: 
Left ventricle/left ventricular; LVEF: Left ventricular ejection fraction; RA: Right 
atrium/right atrial; RV: Right ventricle/right ventricular.
Page 12 of 13Rankin et al. J Cardiovasc Magn Reson          (2021) 23:125 
Supplementary Information
The online version contains supplementary material available at https:// doi. 
org/ 10. 1186/ s12968- 021- 00822-4.
Additional file 1. Supplementary material: S1. Baseline characteristics 
of participants. S2. Summary of clinically significant incidental findings. 
S3. Intra- and inter-observer reproducibility for cardiovascular MRI param-
eters. S4. Determinants of blood pool native T1. S5. Analyses exploring 
the potential influence of intravenous iron therapy on native T1.
Acknowledgements
We wish to thank all participants who kindly volunteered their time for this 
study. We also wish to thank Dr Andrew Morrow for providing the scanner-
specific reference ranges for myocardial native T1 and T2 in healthy individuals.
Authors’ contributions
All authors have reviewed and contributed to this manuscript. PBM, GR, AJR, 
ER and KM conceived the idea and analysis plan for this study. AJR recruited 
participants, performed study visits, analysed the CMRs, analysed the data 
and wrote the manuscript. KM, GR, TT and CB advised on CMR analysis and 
critically reviewed the manuscript. KM also analysed a sample of CMRs for 
inter-observer reproducibility. EE analysed data regarding the determinants of 
blood pool native T1. LD led image acquisition. KAG and JSL assisted with data 
collection, analysis and critically reviewed the manuscript. PBM, ER, RKP and 
AR advised on analysis plan and critically reviewed this manuscript. All authors 
read and approved the final manuscript.
Funding
Dr Alastair Rankin is personally funded by a Clinical Academic Training 
Fellowship from The Chief Scientist Office (Scotland) (CAF/18/02). Dr Elaine 
Rutherford is supported by a Postdoctoral Clinical Lectureship from The Chief 
Scientist Office (Scotland) (PCL/18/03). Dr Jennifer Lees is supported by a 
Postdoctoral Clinical Lectureship from The Chief Scientist Office (Scotland) 
(PCL/20/10). Thomas Treibel is currently supported by a BHF Intermediate fel-
lowship (FS/19/35/34374). Colin Berry is funded by a British Heart Foundation 
Centre of Excellence Award (RE/18/6/34217).
Availability of data and materials
Available via the corresponding author upon reasonable request.
Declarations
Ethics approval and consent to participate
All participants gave written consent prior to participation. Favourable ethical 
opinion was granted by the West of Scotland Research Ethics Committee 1 
(Ref: 18/WS/0138, 13th August 2018).
Consent for publication
All participants gave written consent for their data and/or images to be pub-
lished as part of a scientific report.
Competing interests
The authors declare no competing interests relevant to the present study. 
Outside the present study: Patrick Mark reports speaker honoraria from Vifor-
Fresenius, Astra Zeneca, Janssen, Napp, Novartis and Bristol Myers-Squibb, 
research grants from Boehringer Ingelheim and non-financial support 
from Pharmacosmos. Jennifer Lees reports speaker honoraria from Vifor-Fre-
senius, Astra Zeneca, Bristol Myers-Squibb and Pfizer. Colin Berry is employed 
by the University of Glasgow which holds consultancy and research agree-
ments with Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Causeway 
Therapeutics, Coroventis, Genentech, GSK, HeartFlow, Menarini, and Siemens 
Healthcare.
Author details
1 Institute of Cardiovascular and Medical Sciences, University of Glasgow, 
126 University Place, Glasgow G12 8TA, UK. 2 Renal and Transplant Unit, NHS 
Greater Glasgow and Clyde, Glasgow, UK. 3 Clinical Research Imaging, NHS 
Greater Glasgow and Clyde, Glasgow, UK. 4 Institute for Cardiovascular Sciences 
and Barts Heart Centre, University College London, London, UK. 5 Department 
of Radiology, NHS Greater Glasgow and Clyde, Glasgow, UK. 
Received: 23 September 2021   Accepted: 18 October 2021
References
 1. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in 
chronic renal failure. Lancet. 2000;356:147–52.
 2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease 
and the risks of death, cardiovascular events, and hospitalization. N Engl J 
Med. 2004;351:1296–305. https:// doi. org/ 10. 1056/ NEJMo a0410 31.
 3. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong 
PE, et al. Association of estimated glomerular filtration rate and albumi-
nuria with all-cause and cardiovascular mortality in general population 
cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.
 4. Foley RN. Chronic kidney disease and the risk for cardiovascular disease, 
renal replacement, and death in the United States medicare population, 
1998 to 1999. J Am Soc Nephrol. 2005;16:489–95. https:// doi. org/ 10. 
1681/ ASN. 20040 30203.
 5. Methven S, Steenkamp R, Fraser S. UK renal registry 19th annual report: 
chapter 5 survival and causes of death in UK adult patients on renal 
replacement therapy in 2015: national and centre-specific analyses. 
Nephron. 2017;137(Suppl 1):117–50.
 6. Saravanan P, Davidson NC. Risk assessment for sudden cardiac death in 
dialysis patients. Circ Arrhythm Electrophysiol. 2010;3:553–9.
 7. USRDS. USRDS annual data report: epidemiology of kidney disease in the 
United States. Am J Kidney Dis. 2016;2017(69):S659–88.
 8. Herzog CA. Cardiac arrest in dialysis patients: approaches to alter an 
abysmal outcome. Kidney Int Suppl. 2003;63:S197-200.
 9. Edwards NC, Moody WE, Chue CD, Ferro CJ, Townend JN, Steeds RP. 
Defining the natural history of uremic cardiomyopathy in chronic kidney 
disease: the role of cardiovascular magnetic resonance. JACC Cardiovasc 
Imaging. 2014;7:703–14.
 10. Aoki J, Ikari Y, Nakajima H, Mori M, Sugimoto T, Hatori M, et al. Clinical and 
pathologic characteristics of dilated cardiomyopathy in hemodialysis 
patients. Kidney Int. 2005;67:333–40.
 11. Mall G, Huther W, Schneider J, Lundin P, Ritz E. Diffuse intermyocardio-
cytic fibrosis in uraemic patients. Nephrol Dial Transplant. 1990;5:39–44.
 12. Graham-Brown MPM, Patel AS, Stensel DJ, March DS, Marsh A-M, 
McAdam J, et al. Imaging of myocardial fibrosis in patients with end-
stage renal disease: current limitations and future possibilities. Biomed 
Res Int. 2017;2017:1–14.
 13. Mark PB, Johnston N, Groenning BA, Foster JE, Blyth KG, Martin TN, et al. 
Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac 
magnetic resonance imaging. Kidney Int. 2006;69:1839–45.
 14. Schietinger BJ, Brammer GM, Wang H, Christopher JM, Kwon KW, 
Mangrum AJ, et al. Patterns of late gadolinium enhancement in chronic 
hemodialysis patients. JACC Cardiovasc Imaging. 2008;1:450–6.
 15. Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris STW, 
et al. Gadolinium-enhanced MR imaging and nephrogenic systemic 
fibrosis: retrospective study of a renal replacement therapy cohort. Radi-
ology [Internet]. 2007;245:168–75. https:// doi. org/ 10. 1148/ radiol. 24510 
70353.
 16. Bruce R, Wentland AL, Haemel AK, Garrett RW, Sadowski DR, Djamali 
A, et al. Incidence of nephrogenic systemic fibrosis using gadobenate 
dimeglumine in 1423 patients with renal insufficiency compared with 
gadodiamide. Invest Radiol. 2016;51:701–5.
 17. Badve SV, Palmer SC, Strippoli GFM, Roberts MA, Teixeira-Pinto A, 
Boudville N, et al. The validity of left ventricular mass as a surrogate end 
point for all-cause and cardiovascular mortality outcomes in people with 
CKD: a systematic review and meta-analysis. Am J Kidney Dis [Internet]. 
2016;68:554–63. https:// doi. org/ 10. 1053/j. ajkd. 2016. 03. 418.
 18. Taylor AJ, Salerno M, Dharmakumar R, Jerosch-Herold M. T1 Mapping 
basic techniques and clinical applications [Internet]. JACC Cardiovasc. 
Imaging. 2016
 19. Rutherford E, Talle MA, Mangion K, Bell E, Rauhalammi SM, Roditi G, et al. 
Defining myocardial tissue abnormalities in end-stage renal failure with 
Page 13 of 13Rankin et al. J Cardiovasc Magn Reson          (2021) 23:125  
cardiac magnetic resonance imaging using native T1 mapping. Kidney 
Int. 2016;90:1–8.
 20. Graham-Brown MPM, March DS, Churchward DR, Stensel DJ, Singh A, 
Arnold R, et al. Novel cardiac nuclear magnetic resonance method for 
noninvasive assessment of myocardial fibrosis in hemodialysis patients. 
Kidney Int. 2016;90:835–44.
 21. Graham-Brown MPM, Rutherford E, Levelt E, March DS, Churchward DR, 
Stensel DJ, et al. Native T1 mapping: inter-study, inter-observer and inter-
center reproducibility in hemodialysis patients. J Cardiovasc Magn Reson. 
2017;19:21.
 22. Bull S, White SK, Piechnik SK, Flett AS, Ferreira VM, Loudon M, et al. Human 
non-contrast T1 values and correlation with histology in diffuse fibrosis. 
Heart. 2013;99:932–7. https:// doi. org/ 10. 1136/ heart jnl- 2012- 303052.
 23. de Meester de RC, Bouzin C, Lazam S, Boulif J, Amzulescu M, Melchior J, 
et al. Histological Validation of measurement of diffuse interstitial myocar-
dial fibrosis by myocardial extravascular volume fraction from Modified 
Look-Locker imaging (MOLLI) T1 mapping at 3 T. J Cardiovasc Magn 
Reson. 2015;17:48.
 24. Antlanger M, Aschauer S, Kammerlander AA, Duca F, Säemann MD, Bon-
derman D, et al. Impact of systemic volume status on cardiac magnetic 
resonance T1 mapping.
 25. Kotecha T, Martinez-Naharro A, Yoowannakul S, Lambe T, Rezk T, Knight 
DS, et al. Acute changes in cardiac structural and tissue characterisation 
parameters following haemodialysis measured using cardiovascular 
magnetic resonance. Sci Rep. 2019;9:1–8. https:// doi. org/ 10. 1038/ 
s41598- 018- 37845-4.
 26. Dill T. Contraindications to magnetic resonance imaging [Internet]. Heart 
2008.
 27. Board of the faculty of Clinical Radiology. Standards for intravascular 
contrast agent administration to adult patients Second edition. R Coll 
Clin Radiol. 2011; 3–15.
 28. Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Frie-
drich MG, et al. Standardized image interpretation and post processing in 
cardiovascular magnetic resonance: Society for Cardiovascular Magnetic 
Resonance (SCMR) Board of Trustees Task Force on Standardized Post 
Processing. J Cardiovasc Magn Reson 2013;15.
 29. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, 
et al. Standardized myocardial sementation and nomenclature for 
tomographic imaging of the heart: a Statement for Healthcare Profes-
sionals from the Cardiac Imaging Committee of the Council on Clinical 
Cardiology of the American Heart Association [Internet]. Circulation. 
2002. https:// doi. org/ 10. 1161/ hc0402. 102975.
 30. Captur G, Gatehouse P, Keenan KE, Heslinga FG, Bruehl R, Prothmann M, 
et al. A medical device-grade T1 and ECV phantom for global T1 map-
ping quality assurance—the T1 Mapping and ECV Standardization in 
cardiovascular magnetic resonance (T1MES) program. J Cardiovasc Magn 
Reson. 2016;18:58.
 31. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of clas-
sifying prognostic comorbidity in longitudinal studies: development and 
validation. J Chronic Dis. 1987;40:373–83.
 32. Hemmelgarn BR, Manns BJ, Quan H, Ghali WA. Adapting the Charlson 
comorbidity index for use in patients with ESRD. Am J Kidney Dis. 
2003;42:125–32.
 33. Petersen SE, Aung N, Sanghvi MM, Zemrak F, Fung K, Paiva JM, et al. 
Reference ranges for cardiac structure and function using cardiovascular 
magnetic resonance (CMR) in Caucasians from the UK Biobank popula-
tion cohort. J Cardiovasc Magn Reson 2017;19.
 34. Puntmann VO, Carr-White G, Jabbour A, Yu CY, Gebker R, Kelle S, et al. 
T1-mapping and outcome in nonischemic cardiomyopathy all-cause 
mortality and heart failure. JACC Cardiovasc Imaging. 2016;9:40–50.
 35. Puntmann VO, Valbuena S, Hinojar R, Petersen SE, Greenwood JP, Kramer 
CM, et al. Society for Cardiovascular Magnetic Resonance (SCMR) expert 
consensus for CMR imaging endpoints in clinical research: part i—ana-
lytical validation and clinical qualification [Internet]. J Cardiovasc Magn 
Reson 2018. http:// creat iveco mmons. org/ publi cdoma in/ zero/1. 0/.
 36. Mangion K, McDowell K, Mark PB, Rutherford E. Characterizing cardiac 
involvement in chronic kidney disease using CMR—a systematic review 
[Internet]. Curr Cardiovasc Imaging Rep. 2018. https:// doi. org/ 10. 1007/ 
s12410- 018- 9441-9.
 37. Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. 
Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a 
comprehensive review. J Cardiovasc Magn Reson. 2016;18:89.
 38. Graham-Brown MPM, Gulsin GS, Poli F, Parke K, Burton JO, McCann GP. 
Differences in native T1 and native T2 mapping between patients on 
hemodialysis and control subjects. Eur J Radiol. 2021;140:109748.
 39. Buchanan C, Mohammed A, Cox E, Köhler K, Canaud B, Taal MW, et al. 
Intradialytic cardiac magnetic resonance imaging to assess cardiovascular 
responses in a short-term trial of hemodiafiltration and hemodialysis. J 
Am Soc Nephrol. 2017;28:1269–77. https:// doi. org/ 10. 1681/ ASN. 20160 
60686.
 40. Graham-Brown MPM, Churchward DR, Hull KL, Preston R, Pickering WP, 
Eborall HC, et al. Cardiac remodelling in patients undergoing in-centre 
nocturnal haemodialysis: results from the MIDNIGHT Study, a non-rand-
omized controlled trial. Blood Purif. 2017;44:301–10.
 41. Hwang IC, Kim HK, Park JB, Park EA, Lee W, Lee SP, et al. Aortic valve 
replacement-induced changes in native T1 are related to prognosis in 
severe aortic stenosis: T1 mapping cardiac magnetic resonance imaging 
study. Eur Heart J Cardiovasc Imaging. 2020;21:653–63.
 42. Nakamori S, Fahmy A, Jang J, El-Rewaidy H, Neisius U, Berg S, et al. 
Changes in myocardial native T 1 and T 2 after exercise stress a noncon-
trast CMR pilot study. JACC Cardiovasc Imaging. 2019. https:// doi. org/ 10. 
1016/j. jcmg. 2019. 05. 019.
 43. Liu D, Borlotti A, Viliani D, Jerosch-Herold M, Alkhalil M, De Maria GL, 
et al. CMR native T1 mapping allows differentiation of reversible versus 
irreversible myocardial damage in ST-segment-elevation myocardial 
infarction: an OxAMI Study (Oxford Acute Myocardial Infarction). Circ 
Cardiovasc Imaging. 2017. https:// doi. org/ 10. 1161/ CIRCI MAGING. 116. 
00598 6/-/ DC1.
 44. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman 
P, et al. Clinical recommendations for cardiovascular magnetic resonance 
mapping of T1, T2, T2 and extracellular volume: a consensus statement 
by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed 
by the European Association for Cardiovascular Imaging. J Cardiovasc 
Magn Reson. 2017;19:1–24.
 45. Bloem JL, Reijnierse M, Huizinga TWJ, Van Der Helm-Van Mil AHM. MR 
signal intensity: staying on the bright side in MR image interpretation. 
RMD Open. 2018;4:728.
 46. Rankin AJ, Zhu L, Mangion K, Rutherford E, Gillis KA, Lees JS, et al. 
Global longitudinal strain by feature-tracking cardiovascular magnetic 
resonance imaging predicts mortality in patients with end-stage kidney 
disease. Clin Kidney J. 2021. https:// doi. org/ 10. 1093/ ckj/ sfab0 20/ 61263 73.
 47. Rutherford E, Weir-McCall JR, Patel RK, Houston JG, Roditi G, Struthers 
AD, et al. Research cardiac magnetic resonance imaging in end stage 
renal disease—incidence, significance and implications of unexpected 
incidental findings. Eur Radiol Springer Verlag. 2017;27:315–24.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
